MedCity News May 8, 2024
Marissa Plescia

Transcarent recently announced that it raised $126 million in Series D funding led by General Catalyst and 7wireVentures. When asked what his exit strategy is, CEO Glen Tullman said he does not want to sell Transcarent, but sees an initial public offering as an option.

After care navigation company Transcarent announced last week that it raised $126 million in Series D funding, CEO Glen Tullman told MedCity News that he has “no interest” in selling the company. However, an initial public offering (IPO) — when a privately owned company sells shares of stock to the public — is a possibility, he said.

“I have run four public companies and have gone through three IPOs, so it’s a question I often...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Digital Health, Insurance, Self-insured, Technology
Culina Health Snags $7.9M to Expand Access to Nutrition Care
ŌURA Promises Relentless Innovation As It Hits New Oura Ring Milestone
Digital Twins Aren’t Just for Big Businesses
How Did Digital Health Investors View This Year’s Funding Environment — and What Do They Predict for 2025?
Google's top 10 healthcare moves of '24

Share This Article